NCT01455870View on ClinicalTrials.gov

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

535

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Type 2 Diabetes
Interventions
DRUG

ITCA 650 60 mcg/day

exenatide in DUROS

DRUG

sitagliptin

oral sitagliptin 100 mg/day

Trial Locations (54)

2301

Brockton

2650

Hvidovre

11218

Brooklyn

13760

Endwell

15401

Uniontown

27103

Winston-Salem

28557

Morehead City

30114

Canton

33026

Pembroke Pines

33126

Miami

33134

Coral Gables

33162

North Miami Beach

33432

Boca Raton

33765

Clearwater

35235

Birmingham

37431

Bad Lauterberg im Harz

38119

Memphis

45227

Cincinnati

45429

Kettering

46123

Avon

46131

Franklin

46140

Greenfield

46383

Valparaiso

47304

Muncie

48098

Troy

49684

Traverse City

51000

Rijeka

59101

Billings

60607

Chicago

60634

Chicago

63110

St Louis

67205

Wichita

67208

Wichita

68510

Lincoln

70006

Metairie

73069

Norman

75230

Dallas

75390

Dallas

77083

Houston

77375

Tomball

77478

Sugar Land

78229

San Antonio

78414

Corpus Christi

85224

Chandler

89148

Las Vegas

90017

Los Angeles

90807

Long Beach

91607

Valley Village

92101

San Diego

92780

Tustin

94401

San Mateo

94598

Walnut Creek

97701

Bend

LV1002

Riga

Sponsors
All Listed Sponsors
lead

Intarcia Therapeutics

INDUSTRY